Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PRR11 promotes ccRCC tumorigenesis by regulating E2F1 stability
Siming Chen, Zhiwen He, Tianchen Peng, Fenfang Zhou, Gang Wang, Kaiyu Qian, Lingao Ju, Yu Xiao, Xinghuan Wang
Siming Chen, Zhiwen He, Tianchen Peng, Fenfang Zhou, Gang Wang, Kaiyu Qian, Lingao Ju, Yu Xiao, Xinghuan Wang
View: Text | PDF
Research Article Cell biology Nephrology

PRR11 promotes ccRCC tumorigenesis by regulating E2F1 stability

  • Text
  • PDF
Abstract

Proline rich 11 (PRR11), a novel tumor-related gene, has been identified in different tumors. However, the relevant biological functions of PRR11 in human clear cell renal cell carcinoma (ccRCC) have not been studied. In this study, we first identified PRR11 as a biomarker of ccRCC and predictor of poor prognosis by bioinformatics. Then, we showed that PRR11 silencing substantially reduced ccRCC cell proliferation and migration in vitro and in vivo. Importantly, we found that PRR11 induced the degradation of the E2F1 protein through its interaction with E2F1, and PRR11 reduced the stability of the E2F1 protein in ccRCC cells, thereby affecting cell cycle progression. Further results indicated that the downregulation of E2F1 expression partially reversed the changes in ccRCC cell biology caused by PRR11 deletion. In addition, we showed that PRR11 was a target gene of c-Myc. The transcription factor c-Myc may have promoted the expression of PRR11 in ccRCC cells by binding to the PRR11 promoter region, thereby accelerating the progression of ccRCC. In summary, we found that PRR11 served as an oncogene in ccRCC, and PRR11 reduced the protein stability of E2F1 and could be activated by c-Myc.

Authors

Siming Chen, Zhiwen He, Tianchen Peng, Fenfang Zhou, Gang Wang, Kaiyu Qian, Lingao Ju, Yu Xiao, Xinghuan Wang

×

Figure 7

PRR11 reduced the stability of the E2F1 protein by interacting with E2F1.

Options: View larger image (or click on image) Download as PowerPoint
PRR11 reduced the stability of the E2F1 protein by interacting with E2F1...
(A) Western blotting analysis of ACHN cells and Caki-1 cells subjected to double thymidine blocking (n = 3). (B) Co-IP assay of exogenous E2F1 protein and PRR11 protein was performed in 293T cells (n = 3). (C) Co-IP assay of endogenous E2F1 protein and PRR11 protein was performed in ACHN cells (n = 3). (D) The colocalization of PRR11 and E2F1 in ACHN cells was analyzed by observing fluorescence signals by confocal immunofluorescence microscopy. Scale bar: 15 μm. (E) The effect of PRR11 on E2F1 protein levels in ACHN cells was analyzed by Western blotting (n = 3). (F–H) The effect of PRR11 on E2F1 protein degradation was investigated with the exogenous and endogenous expression of the proteins by an CHX assay (n = 3). (I–K) Quantification of E2F1 protein degradation rate (n = 3). Two-tailed t test (I) and 1-way ANOVA with Dunnett’s multiple comparisons test (J and K) analyses were performed. *P < 0.05, **P < 0.01, ***P < 0.001. PRR11, proline rich 11; Co-IP, coimmunoprecipitation; CHX, cycloheximide.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts